Factores asociados al desarrollo de lupus eritematoso sistémico en pacientes con lupus cutáneo

dc.contributor.advisorCortes Correa, Carolina Ivettespa
dc.contributor.advisorPeñaranda Contreras, Elkin Omarspa
dc.contributor.advisorFranco, Robertospa
dc.contributor.authorBerrío Flórez, Paula Gabrielaspa
dc.date.accessioned2021-01-29T21:41:14Zspa
dc.date.available2021-01-29T21:41:14Zspa
dc.date.issued2020spa
dc.description.abstractImportance: Up to 28% of patients with cutaneous lupus erythematosus (CLE) develop systemic lupus erythematosus (SLE). Studies aimed at identifying additional risk factors for progression to systemic disease are scarce and in the case of Latin America, nonexistent. Objective: To determine factors associated with the development of SLE in patients with cutaneous lupus. Methods: Observational, analytical, case-control study (n = 142). A comparative analysis is performed between patients with cutaneous lupus who developed (cases) and did not develop systemic lupus (controls) between 2013 and 2019 in a reference hospital. Main measures: Demographic, clinical, paraclinical characteristics and the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score. Results: 71 cases and 71 controls were analyzed; both groups comparable in terms of demographic characteristics. In the multivariate analysis, factors associated with the development of SLE in patients with CEL were identified: location of lesions on the trunk (OR 5.08, 95% CI 1.76-14.6, p 0.003), location of lesions in upper limbs (OR 4.52, 95% CI 1.75-11.6, p 0.002), CLASI damage score greater than or equal to 3 (OR 3.48, 95% CI 1.29-9.38, p 0.013) and the presence of hematological alterations (OR 4.24, 95% CI 1.23-14.5, p 0.021). Conclusions: In patients with cutaneous lupus, regardless of their phenotype, physical skin examinations should be performed periodically with special attention to changes in location and sequelae of damage to the lesions, as well as hematological monitoring as these could represent a red flag towards the development of SLE.spa
dc.description.abstractImportancia: El lupus eritematoso cutáneo (LEC) implica una probabilidad hasta del 28% de desarrollar lupus eritematoso sistémico (LES) y los estudios dirigidos a identificar factores de riesgo adicionales de progresión a enfermedad sistémica son escasos y en el caso de Latinoamérica, inexistentes. Objetivo: Determinar factores asociados al desarrollo de LES en pacientes con lupus cutáneo. Métodos: Estudio observacional, analítico, de casos y controles no pareados (n=142). Se realiza un análisis comparativo entre los pacientes con lupus cutáneo que desarrollaron (casos) y no desarrollaron lupus sistémico (controles) entre 2013 y 2019 en un hospital de referencia. Principales medidas: Características demográficas, clínicas, paraclínicas y puntaje de Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). Resultados: Se identificaron como principales factores asociados al desarrollo de LES en pacientes con LEC: localización de lesiones en tronco (OR 5.08, IC 1,76-14,6, p 0,003), localización de lesiones en miembros superiores (OR 4.52, IC 1,75-11,6, p 0,002), puntaje de daño CLASI mayor o igual a 3 (OR 3.48, IC 1,29-9,38, p 0,013) y la presencia de alteraciones hematológicas (OR 4.24, IC 1,23-14,5, p 0,021). Conclusiones: En los pacientes con lupus cutáneo, independiente de su fenotipo de compromiso dermatológico y sistémico, deben realizarse de forma periódica exámenes físicos de la piel con especial atención a cambios en localización y secuelas de daño de las lesiones, así como seguimiento hematológico; ya estos podrían representar una bandera roja hacia el desarrollo de LES.spa
dc.description.degreelevelEspecialidades Médicasspa
dc.format.extent51spa
dc.format.mimetypeapplication/pdfspa
dc.identifier.citationBerrío Flórez, P. G. (2020). Factores asociados al desarrollo de lupus eritematoso sistémico en pacientes con lupus cutáneo [Tesis de especialidad, Universidad Nacional de Colombia]. Repositorio Institucional.spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/78998
dc.language.isospaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.programBogotá - Medicina - Especialidad en Dermatologíaspa
dc.relation.referencesMéndez-Flores S, Tinoco-Fragoso F, Hernández-Molina G. Artículos de revisión Lupus eritematoso cutáneo, una entidad multidimensional Cutaneous lupus erythematosus, a multidimensional entity. Rev Med Inst Mex Seguro Soc. 2015;53(6):764–72.spa
dc.relation.referencesPowers DB. Systemic Lupus Erythematosus and Discoid Lupus Erythematosus. Oral Maxillofac Surg Clin North Am. 2008;20(4):651–62.spa
dc.relation.referencesFava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun [Internet]. 2018/11/16. 2019 Jan;96:1–13. Available from: https://pubmed.ncbi.nlm.nih.gov/30448290spa
dc.relation.referencesTull TJ, Pink AE, Benton EC, D’Cruz D. Cutaneous lupus erythematosus. Br J Hosp Med. 2015;76(11):C162–5.spa
dc.relation.referencesHernández Zapata LJ, Alzate Vanegas SI, Eraso RM, Yepes Delgado CE. Lupus, «un cáncer pero más chiquito». Percepciones del lupus eritematoso sistémico en adolescentes próximos a la transición. Rev Colomb Reumatol. 2018;25(3):151–60.spa
dc.relation.referencesHejazi EZ, Werth VP. Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. Am J Clin Dermatol. 2016;17(2):135–46.spa
dc.relation.referencesZhu TY, Tam LS, Li EK. Cost-of-illness studies in systemic lupus erythematosus: A systematic review. Arthritis Care Res (Hoboken). 2011 May;63(5):751–60.spa
dc.relation.referencesPeláez I, Cuervo F, Angarita I, Londo J, Giraldo R, Camilo J, et al. Prevalencia de la enfermedad reumática en Colombia , según estrategia COPCORD-Asociación prevalencia de enfermedad reumática en población colombiana mayor de 18 a nos. Rev Colomb Reumatol. 2018;5(4):245–56.spa
dc.relation.referencesFernández D, Rincon-Riaño D, Bernal-Macías S, Dávila J, Rosselli D. Prevalencia y características demográficas del Lupus Eritematoso Sistémico, Miopatía Inflamatoria, Osteoporosis, Polimialgia Reumática, Síndrome Sjögren y Vasculitis en Colombia, según información del Sistema Integral de Información de la Protección Social. 2017.spa
dc.relation.referencesFors Nieves CE, Izmirly PM. Mortality in Systemic Lupus Erythematosus: an Updated Review. Curr Rheumatol Rep. 2016 Apr;18(4):21.spa
dc.relation.referencesPons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine (Baltimore). 2004 Jan;83(1):1–17.spa
dc.relation.referencesCavallasca JA, Del Rosario Maliandi M, Sarquis S, Nishishinya MB, Schvartz A, Capdevila A, et al. Outcome of patients with systemic rheumatic diseases admitted to a medical intensive care unit. J Clin Rheumatol Pract reports Rheum Musculoskelet Dis. 2010 Dec;16(8):400–2.spa
dc.relation.referencesAguirre-Valencia D, Suárez-Avellaneda A, Ocampo-Piraquive V, Posso-Osorio I, Naranjo-Escobar J, Nieto-Aristizábal I, et al. Mortality in patients with systemic lupus erythematosus in Colombia: a case series. Clin Rheumatol. 2019 Jul;38(7):1865–71.spa
dc.relation.referencesWalling H, Sontheimer R. Cutaneous lupus erythematosus: Issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365–81.spa
dc.relation.referencesWerth VP. Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev. 2005 Jun;4(5):296–302.spa
dc.relation.referencesKuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;48–49:14–9.spa
dc.relation.referencesKuhn A, Amler S, Beissert S, Böhm M, Brehler R, Ehrchen J, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): A modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. 2010;163(1):83–92.spa
dc.relation.referencesAlbrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. Outcome Instrument for Cutaneous Lupus Erythematosus. J Invest Dermatol. 2005;125(5):889–94.spa
dc.relation.referencesBonilla-Martinez ZL, Albrecht J, Troxel AB, Taylor L, Okawa J, Dulay S, et al. The cutaneous lupus erythematosus disease area and severity index: A responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol. 2008;144(2):173–80.spa
dc.relation.referencesChong BF, Song J, Olsen NJ. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol. 2012 Jan;166(1):29–35.spa
dc.relation.referencesGrönhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011 Jun;164(6):1335–41.spa
dc.relation.referencesCallen JP. Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Arch Dermatol. 1982 Jun;118(6):412–6.spa
dc.relation.referencesHealy E, Kieran E, Rogers S. Cutaneous lupus erythematosus--a study of clinical and laboratory prognostic factors in 65 patients. Ir J Med Sci. 1995;164(2):113–5spa
dc.relation.referencesInsawang M, Kulthanan K, Chularojanamontri L, Tuchinda P. Discoid lupus erythematosus: Description of 130 cases and review of their natural history and clinical course. J Clin Immunol Immunopathol Res. 2010;2(1):1–8.spa
dc.relation.referencesMurphy B, McCourt C, O’Kane D. Risk factors for development of systemic lupus erythematosus in patients with cutaneous lupus: a retrospective review. Clin Exp Dermatol. 2019;44(2):e26–7.spa
dc.relation.referencesWieczorek IT, Propert KJ, Okawa J, Werth VP. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatology. 2014;150(3):291–6.spa
dc.relation.referencesDurosaro O, Davis MDP, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. 2009 Mar;145(3):249–53.spa
dc.relation.referencesCardinali C, Caproni M, Bernacchi E, Amato L, Fabbri P. The spectrum of cutaneous manifestations in lupus erythematosus--the Italian experience. Lupus. 2000;9(6):417–23.spa
dc.relation.referencesNg PP, Tan SH, Koh ET, Tan T. Epidemiology of cutaneous lupus erythematosus in a tertiary referral centre in Singapore. Australas J Dermatol. 2000 Nov;41(4):229–33.spa
dc.relation.referencesSCOTT A, REES EG. The relationship of systemic lupus erythematosus and discoid lupus erythematosus; a clinical and hematological study. AMA Arch Derm. 1959 Apr;79(4):422–35.spa
dc.relation.referencesWalocko F, Black S, Anderson S, Li X, Adams-Huet B, Chong B. Worsening skin damage in patients with cutaneous lupus erythematosus may predict development of systemic lupus erythematosus. J Am Acad Dermatol [Internet]. 2020; Available from: https://doi.org/10.1016/j.jaad.2020.05.020spa
dc.relation.referencesFlynn A, Gilhooley E, O’Shea F, Wynne B. The use of SLICC and ACR criteria to correctly label patients with cutaneous lupus and systemic lupus erythematosus. Clin Rheumatol. 2018;37(3):817–8.spa
dc.relation.referencesTiao J, Feng R, Carr K, Okawa J, Werth VP. Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE). J Am Acad Dermatol. 2016 May;74(5):862–9.spa
dc.relation.referencesPons-Estel GJ, Aspey LD, Bao G, Pons-Estel BA, Wojdyla D, Saurit V, et al. Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: Longitudinal data from a large Latin American cohort. Lupus. 2017;26(1):73–83.spa
dc.rightsDerechos reservados - Universidad Nacional de Colombiaspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial-SinDerivadas 4.0 Internacionalspa
dc.rights.spaAcceso abiertospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.subject.ddc610 - Medicina y saludspa
dc.subject.proposalCLASIspa
dc.subject.proposalCLASIeng
dc.subject.proposalCutaneous lupus erythematosuseng
dc.subject.proposalLupus eritematoso cutáneospa
dc.subject.proposalLupus eritematoso sistémicospa
dc.subject.proposalSystemic lupus erythematosuseng
dc.subject.proposalHematologiceng
dc.subject.proposalHematológicospa
dc.subject.proposalLesiones cutáneasspa
dc.subject.proposalSkin lesionseng
dc.titleFactores asociados al desarrollo de lupus eritematoso sistémico en pacientes con lupus cutáneospa
dc.typeTrabajo de grado - Especialidad Médicaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
PAULA TESIS FINAL VERSION 1.pdf
Tamaño:
665.58 KB
Formato:
Adobe Portable Document Format

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
3.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción: